1. Home
  2. STTK vs RXST Comparison

STTK vs RXST Comparison

Compare STTK & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.00

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Logo RxSight Inc.

RXST

RxSight Inc.

HOLD

Current Price

$7.33

Market Cap

305.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
RXST
Founded
2016
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
305.0M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
STTK
RXST
Price
$6.00
$7.33
Analyst Decision
Buy
Hold
Analyst Count
7
11
Target Price
$7.60
$11.60
AVG Volume (30 Days)
589.2K
684.5K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$134,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$6.62
52 Week High
$6.27
$27.13

Technical Indicators

Market Signals
Indicator
STTK
RXST
Relative Strength Index (RSI) 71.72 39.37
Support Level $1.85 $7.34
Resistance Level N/A $9.11
Average True Range (ATR) 0.42 0.41
MACD 0.09 0.02
Stochastic Oscillator 89.41 23.81

Price Performance

Historical Comparison
STTK
RXST

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.

Share on Social Networks: